Patents by Inventor Ho Yun Chung

Ho Yun Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11946051
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: April 2, 2024
    Assignee: Tego Science Inc.
    Inventors: Saewha Jeon, Ho Yun Chung, Na Ra Oh, Yun Hee Kim, Jikhyon Han, Hyun Ah Moon
  • Publication number: 20230124032
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Application
    Filed: November 21, 2022
    Publication date: April 20, 2023
    Applicant: Tego Science Inc.
    Inventors: Saewha JEON, Ho Yun CHUNG, Na Ra OH, Yun Hee KIM, Jikhyon HAN, Hyun Ah MOON
  • Publication number: 20210388352
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Application
    Filed: December 4, 2019
    Publication date: December 16, 2021
    Applicant: Tego Science Inc.
    Inventors: SaeWha JEON, Ho Yun CHUNG, Na Ra OH, Yun Hee KIM, Jik Hyon HAN, Hyun Ah MOON
  • Publication number: 20140341865
    Abstract: There is provided a dressing for treating a wound. The dressing for healing a wound can be useful in maintaining a moisture environment at a wound site using a biocompatible polymer scaffold, and effectively promoting healing of a wound by various growth factors secreted by skin cells or stem cells attached to the biocompatible polymer scaffold as well.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 20, 2014
    Applicant: TEGO SCIENCE INC.
    Inventors: Saewha Jeon, Yun Hee Kim, Ho Yun Chung, Jin Hyun Choi, Hankyu Jang